Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L.

PLoS One. 2011;6(8):e23937. doi: 10.1371/journal.pone.0023937. Epub 2011 Aug 23.

2.

Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.

Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO.

PLoS One. 2016 Apr 14;11(4):e0153497. doi: 10.1371/journal.pone.0153497. eCollection 2016.

3.

Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.

Liu XL, Pan Q, Zhang RN, Shen F, Yan SY, Sun C, Xu ZJ, Chen YW, Fan JG.

World J Gastroenterol. 2016 Nov 28;22(44):9844-9852.

4.

Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.

Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, Hamajima N, Hashimoto S.

Clin Chim Acta. 2013 Sep 23;424:99-103. doi: 10.1016/j.cca.2013.05.021. Epub 2013 May 30.

PMID:
23727030
5.

Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies.

Lendvai G, Jármay K, Karácsony G, Halász T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A.

World J Gastroenterol. 2014 Nov 7;20(41):15343-50. doi: 10.3748/wjg.v20.i41.15343.

6.

Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.

Tryndyak VP, Latendresse JR, Montgomery B, Ross SA, Beland FA, Rusyn I, Pogribny IP.

Toxicol Appl Pharmacol. 2012 Jul 1;262(1):52-9. doi: 10.1016/j.taap.2012.04.018. Epub 2012 Apr 24.

7.

MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection.

Lee TH, Matta B, King BD, Hodges MR, Tillmann HL, Patel K.

J Med Virol. 2015 Oct;87(10):1722-6. doi: 10.1002/jmv.24230. Epub 2015 May 11.

PMID:
25963774
8.

Expression analysis of liver-specific circulating microRNAs in HCV-induced hepatocellular Carcinoma in Egyptian patients.

Mourad L, El-Ahwany E, Zoheiry M, Abu-Taleb H, Hassan M, Ouf A, Rahim AA, Hassanien M, Zada S.

Cancer Biol Ther. 2018 May 4;19(5):400-406. doi: 10.1080/15384047.2018.1423922. Epub 2018 Feb 16.

9.

Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, Schuppan D.

Gastroenterology. 2012 Aug;143(2):448-58. doi: 10.1053/j.gastro.2012.04.031. Epub 2012 Apr 24.

10.

miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.

Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM.

J Hepatol. 2013 Jan;58(1):119-25. doi: 10.1016/j.jhep.2012.08.008. Epub 2012 Aug 15.

PMID:
22902550
11.

Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease.

Grammatikos G, Mühle C, Ferreiros N, Schroeter S, Bogdanou D, Schwalm S, Hintereder G, Kornhuber J, Zeuzem S, Sarrazin C, Pfeilschifter J.

Biochim Biophys Acta. 2014 Jul;1841(7):1012-20. doi: 10.1016/j.bbalip.2014.04.007. Epub 2014 Apr 25.

PMID:
24769340
12.

Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients.

Butt AM, Raja AJ, Siddique S, Khan JS, Shahid M, Tayyab GU, Minhas Z, Umar M, Idrees M, Tong Y.

Sci Rep. 2016 Feb 22;6:21510. doi: 10.1038/srep21510.

13.

Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

Pais R, Rusu E, Zilisteanu D, Circiumaru A, Micu L, Voiculescu M, Poynard T, Ratziu V.

Eur J Intern Med. 2015 Jan;26(1):30-6. doi: 10.1016/j.ejim.2014.12.001. Epub 2014 Dec 29.

PMID:
25553983
14.

Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease.

García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez de Cía J, Sáez A, Porrero JL, Vargas-Castrillón J, Chávez-Jiménez E, Soto-Fernández S, Díaz A, Gallego-Durán R, Madejón A, Miquilena-Colina ME.

Eur J Clin Invest. 2014 Jan;44(1):65-73. doi: 10.1111/eci.12192. Epub 2013 Nov 23.

PMID:
24134687
15.

Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.

Motawi TK, Shaker OG, El-Maraghy SA, Senousy MA.

PLoS One. 2015 Sep 9;10(9):e0137706. doi: 10.1371/journal.pone.0137706. eCollection 2015.

16.

Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis.

Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M.

J Hepatol. 2013 Feb;58(2):234-9. doi: 10.1016/j.jhep.2012.10.015. Epub 2012 Oct 22.

PMID:
23085648
17.

Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.

Yamada H, Ohashi K, Suzuki K, Munetsuna E, Ando Y, Yamazaki M, Ishikawa H, Ichino N, Teradaira R, Hashimoto S.

Clin Chim Acta. 2015 Jun 15;446:267-71. doi: 10.1016/j.cca.2015.05.002. Epub 2015 May 7.

PMID:
25958847
18.

Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma.

Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A.

PLoS One. 2011;6(10):e26971. doi: 10.1371/journal.pone.0026971. Epub 2011 Oct 31.

19.

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.

Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Kunimoto H, Sorin Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H.

Hepatol Int. 2016 Jul;10(4):647-56. doi: 10.1007/s12072-016-9729-2. Epub 2016 Apr 13.

PMID:
27074850
20.

Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C.

Giannini E, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, Pasini A, Risso D, Lantieri PB, Icardi G, Barreca T, Testa R.

Am J Gastroenterol. 2000 Nov;95(11):3211-7.

PMID:
11095344

Supplemental Content

Support Center